Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations

By A. Singh, Ritesh Gupta, Amerta Ghosh, Anoop Misra. Diabetes & metabolic syndrome, 2020

738 citations recorded by the source corpus.

Background and aims High prevalence of diabetes makes it an important comorbidity in patients with COVID-19. We sought to review and analyze the data regarding the association between diabetes and COVID-19, pathophysiology of the disease in diabetes and management of patients with diabetes who develop COVID-19 infection. Methods PubMed database and Google Scholar were searched using the key terms ‘COVID-19’, ‘SARS-CoV-2’, ‘diabetes’, ‘antidiabetic therapy’ up to April 2, 2020. Full texts of the retrieved articles were accessed. Results There is evidence of increased incidence and severity of COVID-19 in patients with diabetes. COVID-19 could have effect on the pathophysiology of diabetes. Blood glucose control is important not only for patients who are infected with COVID-19, but also for those without the disease. Innovations like telemedicine are useful to treat patients with diabetes in today’s times.

Subfields: Genetics, Infectious Diseases, Neurology

View Paper: https://www.semanticscholar.org/paper/0e201c7d7b6c49daa52494dd1a0243effad1ea35

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

J. Mangat
K. Younis
Zaheeda Hosein
I. Padda
P. Desai
M. Altaf
A. Marinkovic
R. Patidar

Citations in the corpus

Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis (2020, neutral): “also suggested that diabetes is a determinant of severity and mortality of COVID-19 patients [29].”
Comorbidity and its Impact on Patients with COVID-19 (2020, background): “Older adults and people of any age who have underlying medical conditions, such as hypertension and diabetes, have shown worse prognosis [1].”